Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > 3rd day

<< Previous

Bullboard Posts

Next >>

Comment by Chritterson May 25, 2021 9:41am

145 Views

Post# 33259070

RE:RE:RE:RE:RE:RE:3rd day

I'd be ok with a RS if it was only 10/1! But they need more then 10/1 to make the Money up they need, I can see this going 20/1 or even 25/1. They have no money!!

mavericks2020 wrote: yes it's very possible. suppose after the vote for RS 10/1 Mr. Robert Farrell can decide no RS if a big pharma want too buy Claritas at 3 00 dollars or more. perhaps he s in negiciation whit bigger pharma. person know that

<< Previous

Bullboard Posts

Next >>

AI companies to invest in